Literature DB >> 15681717

A prediction rule for selective screening of Chlamydia trachomatis infection.

H M Götz1, J E A M van Bergen, I K Veldhuijzen, J Broer, C J P A Hoebe, E W Steyerberg, A J J Coenen, F de Groot, M J C Verhooren, D T van Schaik, J H Richardus.   

Abstract

BACKGROUND: Screening for Chlamydia trachomatis infections is aimed at the reduction of these infections and subsequent complications. Selective screening may increase the cost effectiveness of a screening programme. Few population based systematic screening programmes have been carried out and attempts to validate selective screening criteria have shown poor performance. This study describes the development of a prediction rule for estimating the risk of chlamydial infection as a basis for selective screening.
METHODS: A population based chlamydia screening study was performed in the Netherlands by inviting 21,000 15-29 year old women and men in urban and rural areas for home based urine testing. Multivariable logistic regression was used to identify risk factors for chlamydial infection among 6303 sexually active participants, and the discriminative ability was measured by the area under the receiver operating characteristic curve (AUC). Internal validity was assessed with bootstrap resampling techniques.
RESULTS: The prevalence of C trachomatis (CT) infection was 2.6% (95% CI 2.2 to 3.2) in women and 2.0% (95% CI 1.4 to 2.7) in men. Chlamydial infection was associated with high level of urbanisation, young age, Surinam/Antillian ethnicity, low/intermediate education, multiple lifetime partners, a new contact in the previous two months, no condom use at last sexual contact, and complaints of (post)coital bleeding in women and frequent urination in men. A prediction model with these risk factors showed adequate discriminative ability at internal validation (AUC 0.78).
CONCLUSION: The prediction rule has the potential to guide individuals in their choice of participation when offered chlamydia screening and is a promising tool for selective CT screening at population level.

Entities:  

Mesh:

Year:  2005        PMID: 15681717      PMCID: PMC1763735          DOI: 10.1136/sti.2004.010181

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  30 in total

1.  Disappointing performance of literature-derived selective screening criteria for asymptomatic Chlamydia trachomatis infection in an inner-city population.

Authors:  I G van Valkengoed; A J Boeke; S A Morré; A J van den Brule; C J Meijer; W Devillé; L M Bouter
Journal:  Sex Transm Dis       Date:  2000-10       Impact factor: 2.830

2.  Internal validation of predictive models: efficiency of some procedures for logistic regression analysis.

Authors:  E W Steyerberg; F E Harrell; G J Borsboom; M J Eijkemans; Y Vergouwe; J D Habbema
Journal:  J Clin Epidemiol       Date:  2001-08       Impact factor: 6.437

3.  The use of classification and regression trees in clinical epidemiology.

Authors:  R J Marshall
Journal:  J Clin Epidemiol       Date:  2001-06       Impact factor: 6.437

4.  Should scoring rules be based on odds ratios or regression coefficients?

Authors:  Karel G M Moons; Frank E Harrell; Ewout W Steyerberg
Journal:  J Clin Epidemiol       Date:  2002-10       Impact factor: 6.437

5.  Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection.

Authors:  K A Fenton; C Korovessis; A M Johnson; A McCadden; S McManus; K Wellings; C H Mercer; C Carder; A J Copas; K Nanchahal; W Macdowall; G Ridgway; J Field; B Erens
Journal:  Lancet       Date:  2001-12-01       Impact factor: 79.321

6.  Determination of Chlamydia trachomatis prevalence in an asymptomatic screening population: performances of the LCx and COBAS Amplicor tests with urine specimens.

Authors:  S A Morré; I G Van Valkengoed; R M Moes; A J Boeke; C J Meijer; A J Van den Brule
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

7.  Selective screening for chlamydial infection: which criteria to use?

Authors:  W C Miller; I F Hoffman; J Owen-O'Dowd; J T McPherson; A Privette; J L Schmitz; G Woodlief; P A Leone
Journal:  Am J Prev Med       Date:  2000-02       Impact factor: 5.043

8.  Is the increase in notifications of Chlamydia trachomatis infections in Sweden the result of changes in prevalence, sampling frequency or diagnostic methods?

Authors:  Hannelore Götz; Johan Lindback; Torvald Ripa; Malin Arneborn; Kristina Ramsted; Karl Ekdahl
Journal:  Scand J Infect Dis       Date:  2002

Review 9.  A systematic review of the prevalence of Chlamydia trachomatis among European women.

Authors:  J S Wilson; E Honey; A Templeton; J Paavonen; P A Mårdh; B Stray-Pedersen
Journal:  Hum Reprod Update       Date:  2002 Jul-Aug       Impact factor: 15.610

10.  Criteria for selective screening for Chlamydia trachomatis.

Authors:  Maarit Paukku; Riika Kilpikari; Mirja Puolakkainen; Hanna Oksanen; Dan Apter; Jorma Paavonen
Journal:  Sex Transm Dis       Date:  2003-02       Impact factor: 2.830

View more
  32 in total

1.  Evaluating novel interventions for chlamydia screening.

Authors:  N Low
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

2.  Journal impact factors for 2006.

Authors:  Rob F Miller; Helen Ward
Journal:  Sex Transm Infect       Date:  2007-08       Impact factor: 3.519

3.  Sexual and reproductive health behaviors of undocumented migrants in Geneva: a cross sectional study.

Authors:  Paul Sebo; Yves Jackson; Dagmar M Haller; Jean-Michel Gaspoz; Hans Wolff
Journal:  J Immigr Minor Health       Date:  2011-06

4.  Assessing association between IWantTheKit risk quiz tool and sexually transmitted infection positivity in male users for sexually transmitted infection screening.

Authors:  Anuj V Patel; Charlotte A Gaydos; Mary Jett-Goheen; Mathilda Barnes; Laura Dize; Perry Barnes; Yu-Hsiang Hsieh
Journal:  Int J STD AIDS       Date:  2017-07-01       Impact factor: 1.359

5.  Regional differences in chlamydia and gonorrhoeae positivity rate among heterosexual STI clinic visitors in the Netherlands: contribution of client and regional characteristics as assessed by cross-sectional surveillance data.

Authors:  Hannelore M Götz; Louise Aam van Oeffelen; Christian J P A Hoebe; Birgit Hb van Benthem
Journal:  BMJ Open       Date:  2019-01-21       Impact factor: 2.692

6.  Prevalence of urogenital Chlamydia trachomatis increases significantly with level of urbanisation and suggests targeted screening approaches: results from the first national population based study in the Netherlands.

Authors:  J van Bergen; H M Götz; J H Richardus; C J P A Hoebe; J Broer; A J T Coenen
Journal:  Sex Transm Infect       Date:  2005-02       Impact factor: 3.519

7.  Chlamydia trachomatis infections in multi-ethnic urban youth: a pilot combining STI health education and outreach testing in Rotterdam, Netherlands.

Authors:  H M Götz; I K Veldhuijzen; J M Ossewaarde; O de Zwart; J H Richardus
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

Review 8.  Screening for genital chlamydia infection.

Authors:  Nicola Low; Shelagh Redmond; Anneli Uusküla; Jan van Bergen; Helen Ward; Berit Andersen; Hannelore Götz
Journal:  Cochrane Database Syst Rev       Date:  2016-09-13

9.  Use of a risk quiz to predict infection for sexually transmitted infections: a retrospective analysis of acceptability and positivity.

Authors:  Charlotte A Gaydos; Mary Jett-Goheen; Mathilda Barnes; Laura Dize; Perry Barnes; Yu-Hsiang Hsieh
Journal:  Sex Transm Infect       Date:  2015-08-18       Impact factor: 3.519

10.  Evaluation design of a systematic, selective, internet-based, Chlamydia screening implementation in the Netherlands, 2008-2010: implications of first results for the analysis.

Authors:  Ingrid V F van den Broek; Christian J P A Hoebe; Jan E A M van Bergen; Elfi E H G Brouwers; Eva M de Feijter; Johannes S A Fennema; Hannelore M Götz; Rik H Koekenbier; Sander M van Ravesteijn; Eline L M Op de Coul
Journal:  BMC Infect Dis       Date:  2010-04-07       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.